Wearables: When Your Fitness Tracker Becomes a Medical Device

A fitness tracker that measures steps, heart rate, and sleep is a wellness device. One that measures blood pressure and assesses cardiovascular risk is a medical device — and may require FDA premarket authorization to operate legally. The regulatory boundary between those two categories became significantly clearer in early 2026, following a warning that caught a major wearable brand in exactly that gap.

The Wellness Carveout and Its Limits

The 21st Century Cures Act created a “general wellness carveout” in 2016, explicitly exempting devices “intended for maintaining or encouraging a healthy lifestyle” from FDA oversight. For a decade, this gave wearable manufacturers significant freedom to innovate without regulatory review. The exemption assumed wellness devices were meaningfully distinct from clinical tools.

WHOOP’s 2025 experience challenged that assumption directly. The FDA issued a warning that WHOOP’s “Blood Pressure Insights” feature required premarket authorization because it assessed cardiovascular health — not merely lifestyle. The feature crossed from wellness monitoring into clinical assessment, and the exemption no longer applied. WHOOP’s challenge prompted the FDA to issue updated general wellness product definitions in early 2026, providing more explicit guidance on where that boundary sits.

The practical implication is more nuanced than a simple on/off boundary. A single device can simultaneously operate under the wellness carveout (activity tracking, calorie estimates, sleep staging) and require premarket authorization (blood pressure assessment, cardiac rhythm analysis) depending on which features are active and how they’re marketed. A wristband monitoring resting heart rate is wellness. The same hardware claiming to detect atrial fibrillation is a medical device requiring clinical validation.

A Three-Dimensional Regulatory Problem

Beyond the FDA, wearables now face scrutiny from three additional regulatory frameworks operating independently. The FTC enforces truthfulness of health claims — marketing language promising “clinical-grade monitoring” triggers a different standard than “wellness insights.” State medical boards can classify continuous physiological assessment as the practice of medicine, implicating licensure requirements that vary by jurisdiction. Reimbursement frameworks — increasingly relevant as employers and insurers integrate wearables into benefit programs — apply their own coverage criteria that don’t map cleanly to FDA classifications.

Wearables that have navigated this well typically distinguish wellness features from clinical features at both the product and marketing level. AliveCor’s KardiaMobile series, for instance, holds explicit FDA clearance as a medical device — it doesn’t market around the wellness exemption because its clinical claims require something stronger. The design decision to seek clearance rather than operate in the exemption gap reflects a judgment about where the category is heading.

Source: Longevity Technology

Content created with AI assistance and reviewed for accuracy.